Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation

BMC Cardiovascular Disorders

Bo Feng⁵  Yang Wang¹  Shi-Xuan Zhang³  Qian Zhao²  Yong-Hua Bi⁵  Wei-Xiao Li⁵  Xiang-Jun Pang⁴  Shi-Chao Feng⁵  Feng Yang⁵ 

[1] Department of Laboratory Animals, General Hospital of Shenyang Military Area Command, No.83, Wenhua Road, Shenhe District, Shenyang, 110840, PR China;Interventional Radiology Department, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, Liaoning, PR China;Dalian University of Technology, No.2 Linggong Road, Ganjingzi District, Dalian City, 116024, Liaoning, PR China;Fei Cheng Hospital of Traditional Chinese Medicine, 024 Chang Shan Street, Feicheng, 271601, Shandong, PR China;Key Laboratory of Diagnostic Imaging and Interventional Radiology, 5 Nanqi Western Road, Shenyang, 110024, Liaoning Province, PR China

关键词: Scanning electron microscopy;    Hyaluronan and chitosan coating;    Endothelial progenitor cells;    Anti-CD34 antibody;   

Others  :  858024
DOI  :  10.1186/1471-2261-12-96

 received in 2012-04-12, accepted in 2012-10-22,  发布年份 2012

【 摘 要 】

Background

Circulating endothelial progenitor cells (EPCs) capture technology improves endothelialization rates of sirolimus-eluting stents (SES), but the problem of delayed re-endothelialization, as well as endothelial dysfunction, has still not been overcome. Therefore, we investigated whether the combination coating of hyaluronan-chitosan (HC) and anti-CD34 antibody applied on an SES (HCASES) can promote endothelialization, while reducing neointimal formation and inflammation.

Methods

Sirolimus-eluting stents(SES), anti-CD34 antibody stents (GS) and HC-anti-CD34 antibody combined with sirolimus-eluting stents (HCASES) were deployed in 54 normal porcine arteries and harvested for scanning electron microscopy (SEM) and histological analysis. The ratio of endothelial coverage above the stents was evaluated by SEM analysis at 7, 14 and 28 days. The percentage of in-stent stenosis was histologically analyzed at 14 and 28 days.

Results

SEM analysis at 7 days showed that endothelial strut coverage was increased in the HCASES group (68±7%) compared with that in the SES group (31±4%, p=0.02). At 14 days, stent surface endothelialization, evaluated by SEM, showed a significantly higher extent of endothelial coverage above struts in the GS (95 ± 2%) and the HCASES groups (87±4%) compared with that in the SES group (51±6%, p=0.02). Histological examination showed that the percentage of stenosis in the HCASES group was not significantly different to that of the SES and GS groups (both p> 0.05). At 28 days, there was no difference in the rates of endothelial coverage between the HCASES and GS groups. The HCASES group showed less stenosis than that in the GS group (P < 0.05), but it was not significantly different from the SES group (P=0.068).

Conclusions

SEM and histology demonstrated that HCASESs can promote re-endothelialization while enhancing antiproliferative effects.

【 授权许可】

   
2012 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Spaulding C, Daemen J, Boersma E, et al.: A pooled analysis of data comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007, 356:989-997.
• [2]Lagerqvist B, James SK, Stenestrand U, et al.: Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019.
• [3]Nakazawa G, Tanabe K, Aoki J, et al.: Sirolimus-Eluting Stents Suppress Neointimal Formation Irrespective of Metallic Allergy. Circ J 2008, 72:893-896.
• [4]Lakshmana K, Pendyala , Xinhua Y, et al.: The First-Generation Drug-Eluting Stents and Coronary Endothelial Dysfunction. J Am Coll Cardiol Intv 2009, 2:1169-1177.
• [5]van den Heuvel M, Sorop O, Batenburg WW, et al.: Specific Coronary Drug-Eluting Stents Interfere With Distal Microvascular Function After Single Stent Implantation in Pigs. J Am Coll Cardiol Intv 2010, 3:723-730.
• [6]Joner M, Finn AV, Farb A, et al.: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
• [7]Curcio A, Torella D, Indolfi C: Mechanisms of Smooth Muscle Cell Proliferation and Endothelial Regeneration After Vascular Injury and Stenting. Circ J 2011, 75:1287-1296.
• [8]van Beusekom HM, Serruys PW: Drug-Eluting Stent Endothelium. J Am Coll Cardiol Intv 2010, 1:76-77.
• [9]Klomp M, Beijk MA, de Winter RJ: Genous endothelial progenitor cell-capturing stent system: a novel stent technology. Expert Rev Med Devices 2009, 6:365-375.
• [10]Gaku N, Granada JF, Alviar CL, et al.: Anti-CD34 Antibodies Immobilized on the Surface of Sirolimus-Eluting Stents Enhance Stent Endothelialization. J Am Coll Cardiol Intv 2010, 3:68-75.
• [11]Rossi ML, Zavalloni D, Gasparini GL, et al.: The first report of late stent thrombosis leading to acute myocardial infarction in patient receiving the new endothelial progenitor cell capture stent. Int J Cardiol 2010, 141:e20-e22.
• [12]Meng S, Liu Z, Shen L, et al.: The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 2009, 30(12):2276-2283.
• [13]Van Der Giessen WJ, Regar E, Harteveld MS, et al.: “Edge Effect”of (32)p radioactive stents is causes by the combination of chronic stent injury and radioactive dose falloff. Circulation 2001, 104:2236-2241.
• [14]Derkx P, Nigg AL, Bosman FT, et al.: Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacry-late-embedded adult human bone in combination with histomorphometry. Bone 1998, 22:367-373.
• [15]Co M, Tay E, Lee CH, et al.: Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am Heart J 2008, 155:128-132.
• [16]Aoki J, Serruys PW, van Beusekom H, et al.: Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005, 45:1574-1579.
• [17]Miglionico M, Patti G, D’Ambrosio A, et al.: Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients. Catheter Cardiovasc Interv 2008, 71:600-604.
• [18]Meng S, Liu Z, Zhong W, et al.: Phosphorylcholine Modified Chitosan:Appetent and Safe material for Cell. Carbohydr Polym 2007, 70:82-88.
• [19]Yin M, Yuan Y, Liu C, et al.: Combinatorial coating of adhesive polypeptide and anti-CD34tibody for improved endothelial cell adhesion and proliferation. J Mater Sci: Mater Med 2009, 20:1513-1523.
• [20]Celik T, Iyisoy A, Kursaklioglu H, et al.: The forgotten layer of in-stent restenosis: Endothelial dysfunction. Int J Cardiol 2008, 126:443-444.
• [21]Joner M, Nakazawa G, Finn AV, et al.: Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008, 52:333-342.
• [22]Chen TG, Chen JZ, Wang XX: Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 2006, 39:117-125.
• [23]Heleen MM, Oana Sorop M, et al.: Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimus-and tacrolimus-eluting stents. Eurointervention 2010, 6:117-125.
• [24]Butzal M, Loges S, Schweizer M, et al.: Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004, 300:65-71.
• [25]Li JJ, Li J, Nan JL, et al.: Coronary restenotic reduction of Drug-eluting stenting may be due to its anti-inflammatory effect. Med Hypotheses 2007, 69(5):1004-1009.
• [26]Adkins JR, Castresana MR, Wang Z, et al.: Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. Am Surg 2004, 70(5):384-387.
• [27]Higo T, Ueda Y, Oyabu J, et al.: Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. J Am Coll Cardiol Img 2009, 2:616-624.
• [28]Nakazawa G, Vorpahl M, Finn AV, et al.: One step forward and two steps back with drug-eluting-stents from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Img 2009, 2:625-628.